REPARE THERAPEUTICS INC.
7.80%
3,300,856
1808158
760273102
Dec 19, 2024
Dec 26, 2024, 04:34 PM
Reporting Persons (11)
This is a joint filing. The reported shares may overlap between reporting persons and should not be summed.
| Name | Type | % of Class | Aggregate | Sole Voting | Shared Voting |
|---|---|---|---|---|---|
| ANSBERT GADICKE | Individual | 7.80% | 3,300,856 | 0 | 3,300,856 |
| Todd Foley | Individual | 4.50% | 1,906,670 | 0 | 1,906,670 |
| MPM BioVentures 2014 LLC | Other | 4.50% | 1,906,670 | 0 | 1,906,670 |
| LUKE EVNIN | Individual | 4.50% | 0 | 0 | 1,906,670 |
| MPM BioVentures 2014 GP LLC | Other | 4.30% | 1,847,067 | 0 | 1,847,067 |
| MPM BioVentures 2014, L.P. | Partnership | 4.10% | 1,731,575 | 1,731,575 | 0 |
| MPM BioImpact LLC | Other | 3.30% | 1,394,186 | 0 | 1,394,186 |
| Oncology Impact Fund (Cayman) Management L.P. | Partnership | 3.30% | 1,394,186 | 0 | 1,394,186 |
| UBS Oncology Impact Fund L.P. | Partnership | 3.30% | 1,394,186 | 1,394,186 | 0 |
| MPM BioVentures 2014 (B), L.P. | Partnership | 0.30% | 115,492 | 115,492 | 0 |
| MPM Asset Management Investors BV2014 LLC | Other | 0.10% | 59,603 | 59,603 | 0 |
Disclosure Items (4)
Common Shares
REPARE THERAPEUTICS INC.
7171 FREDERICK BANTING, SAINT-LAURENT, A8, H4S 1Z9
The entities and persons filing this statement are MPM BioVentures 2014, L.P. ('BV 2014'), MPM BioVentures 2014 (B), L.P. ('BV 2014(B)'), MPM Asset Management Investors BV2014 LLC ('AM BV2014 LLC'), UBS Oncology Impact Fund L.P. ('UBS Oncology'), MPM BioVentures 2014 GP LLC ('BV 2014 GP'), MPM BioVentures 2014 LLC ('BV 2014 LLC'), Oncology Impact Fund (Cayman) Management LP ('Oncology Cayman') and MPM BioImpact LLC ('BioImpact') (collectively, the 'MPM Entities') and Ansbert Gadicke, Luke Evnin and Todd Foley (collectively, the 'Listed Persons' and, together with the MPM Entities, the 'Filing Persons'). The Filing Persons expressly disclaim status as a 'group' for purposes of this Schedule 13D.
The address of the principal place of business for each of the MPM Entities and Ansbert Gadicke, Luke Evnin and Todd Foley is 399 Boylston Street, Suite 1100, Boston, MA 02116.
The principal business of each of the Filing Persons is the venture capital investment business.
During the last five years, none of the Filing Persons has been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree, or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.
Each of the Listed Persons is a United States citizen and each of the MPM Entities is a Delaware limited partnership or limited liability company, other than UBS Oncology and Oncology Cayman which are Cayman Islands limited partnerships. In accordance with the provisions of General Instruction C to Schedule 13D, information concerning the managers and each other person controlling the general partners of the MPM Entities required by Item 2 of Schedule 13D is listed on Schedule 1 to this Amendment No. 4 and is incorporated by reference herein.
See rows (11) and (13) of the Filing Persons Owner Profile of this Amendment No. 4 for the aggregate number of Common Shares and percentages of the shares of Common Shares beneficially owned by the Filing Person. The Common Shares are held as follows: • 1,731,575 shares are held directly by BV 2014; • 115,492 shares are held directly by BV 2014(B); • 59,603 shares are held directly by AM BV2014 LLC; and • 1,394,186 shares are held directly by UBS Oncology. BV 2014 GP and BV 2014 LLC are the direct and indirect general partners of BV 2014 and BV 2014(B) and, accordingly, may be deemed to beneficially own the shares held by BV 2014 and BV 2014(B). BV 2014 LLC is the managing member of AM BV2014 LLC and, accordingly, may be deemed to beneficially own the shares held by AM BV2014 LLC. BioImpact and Oncology Cayman are the direct and indirect general partners of UBS Oncology and, accordingly, may be deemed to beneficially own the shares held by UBS Oncology. Drs. Gadicke and Evnin and Mr. Foley are the managing directors of BV 2014 LLC and, accordingly, may be deemed to beneficially own the shares held by BV 2014, BV 2014(B) and AM BV2014 LLC. Dr. Gadicke is the managing partner of BioImpact and, accordingly may be deemed to beneficially own the shares held by UBS Oncology. Calculation of the percentage of the shares of Common Shares beneficially owned is based upon 42,510,708 share of Common Shares outstanding as of November 1, 2024, as reported in the Issuer's Form 10-Q filed with the SEC on November 7, 2024.
See rows (7) through (10) of the Filing Persons Owner Profile of this Amendment No. 4 for the number of shares as to which there is sole power to vote or to direct the vote, sole power to dispose or to direct the disposition, or shared power to dispose or to direct the disposition.
The Reporting Persons sold the following Common Shares in the open market in the sixty days preceding the date of this filing: Date of Sale Price Range Ave. Price Sold by Sold by Sold By AM BV Sold by BV 2014 BV 2104(B) 2014 LLC UBS Oncology 12/13/24 $1.66-$2.01 $1.82 154,827 10,327 5,329 124,659 12/17/24 $1.45-$1.535 $1.48 13,565 905 466 10,922 12/18/24 $1.23-$1.33 $1.28 17,685 1,180 609 14,239 12/19/24 $1.265-$1.37 $1.33 31,717 2,115 1,092 25,537 12/20/24 $1.305-$1.45 $1.37 60,426 4,030 2,080 48,652 12/23/24 $1.27-$1.36 $1.32 26,894 1,794 925 21,654
Inapplicable.
Inapplicable.
Joint Filing Statement